PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 12, 20250 citations

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

View Full Paper
NSNiccolò G. SantinNSNamrata SethiSBStefania Bellone

Key Points

  • Datopotamab deruxtecan shows significantly lower IC50 in TROP2 expressing cell lines compared to control.
  • In cell lines with TROP2 expression, Dato-DXd exhibited lower IC50 values, with P < 0.05 for significance.
  • Control ADC displayed no significant difference in IC50 against the cell line with 0 TROP2 expression.
  • Cytotoxicity was evaluated using flow cytometry, establishing dose-response relationships for the drug.

Abstract

Flow cytometry–based cytotoxicity assay. Determination of Dato-DXd and control ADC IC50 (mean SEM) in the tested cell lines. A, Cell line with 0 TROP2 expression i.e., END(K)34 showed no difference in the IC50 of Dato-DXd and control ADC. B and C, Cell lines with high TROP2 expression 3+; i.e., END(K)254 and END(K)265 demonstrated significantly lower IC50 for Dato-DXd when compared with control ADC (P

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Santin et al. (2025) studied this question.

synapsesocial.com/papers/68d44b3031b076d99fa54927https://doi.org/10.1158/2767-9764.30102521
Ask AI
Helpful
Bookmark
Share
View Full Paper